Nifural oral suspension 200mg/5ml, 90ml

Composition

>

of 5 ml of suspension contains:

Active ingredient:

nifuroxazide 200 mg;

excipients: sucrose (sugar), sodium hydroxide, methyl parahydroxybenzoate, carbomer, citric acid monohydrate, banana flavor, ethanol (ethyl alcohol) 96%, purified water.

Pharmacological action

Pharmacotherapeutic group antimicrobial agent-nitrofuran. KodATH: A 07 AH 03Pharmacological actionpharmacodynamicanifuroxazide is an antimicrobial agent derived from nitrofuran. It blocks the activity of dehydrogenases and inhibits respiratory chains, the tricarboxylic acid cycle, and a number of other biochemical processes in the microbial cell. Destroys the membrane of the microbial cell, reduces the production of toxins by microorganisms. Highly active against Campylobacterjejuni, Escherichiacoli, Salmonellaspp, Shigellaspp., Clostridiumperfingens, Vibriocholerae, pathogenic Vibrions and Vibrioparahaemolytique, Staphylococcusspp. Weakly sensitive to nifuroxazide: Citrobacterspp, Enterobactercloacae and Proteusindologenes. Resistant to nifuroxazide: Klebsiellaspp, Proteusmirabilis, Providenciaspp, Pseudomonasspp. It does not disturb the balance of intestinal microflora. In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection. Pharmacokineticsafter oral use, nifuroxazide is practically not absorbed from the digestive tract and has its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestines: 20% unchanged, and the rest of the amount of nifuroxazide is chemically altered.

Indications

Acute bacterial diarrhea that occurs without deterioration of the general condition, fever, intoxication.

Use during pregnancy and lactation

No teratogenic effect was found in animal studies. However, as a precautionary measure, taking nifuroxazide during pregnancy is not recommended.

During the period of breastfeeding, it is possible to continue breastfeeding in the case of a short course of treatment with the drug. It is necessary to consult a doctor.

Contraindications

Hypersensitivity to nifuroxazide, nitrofuran derivatives and other components of the drug, pregnancy, neonatal period up to 1 month, prematurity, fructose intolerance, glucose-galactose malabsorption syndrome, sucrose and isomaltase insufficiency. With caution liver diseases, alcoholism, traumatic brain injury, brain diseases, lactation, childhood.

Side effects

Allergic reactions (skin rash, urticaria, angioedema, anaphylactic shock). If any of the side effects listed in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Concomitant use with drugs that cause the development of disulfiram-like reactions, drugs that inhibit the function of the central nervous system is not recommended. If you are taking other medications (including over-the-counter medications), consult your doctor before using Nifural®.

How to take, course of use and dosage

It is applied inside.

For dosing, a 5 ml metered spoon is used, which has a graduation of 2.5 ml.

The suspension should be shaken well before use.

Children from 1 to 6 months: 100 mg of nifuroxazide (2.5 ml of suspension) 2-3 times a day (the interval between doses is 8-12 hours).

Children from 6 months to 3 years: 100 mg of nifuroxazide (2.5 ml suspension) 3 times a day (8 hours interval between doses).

Children from 3 to 6 years: 200 mg of nifuroxazide (5 ml of suspension) 3 times a day (8 hours interval between doses).

Children from 6 to 18 years: 200 mg of nifuroxazide (5 ml of suspension) 3-4 times a day(the interval between doses is 6-8 hours).

For adults: 200 mg of nifuroxazide (5 ml of suspension) 4 times a day (6 hours interval between doses).

The duration of treatment is 5-7 days, but not more than 7 days. If there is no improvement during the first 3 days of taking it, then you should consult a doctor.

Use the drug only according to the method of use and in the doses indicated in the instructions. If necessary, please consult your doctor before using the medicine.

Overdose

Symptoms of overdose are not known. Treatment is symptomatic.

Special instructions

When treating diarrhea simultaneously with nifuroxazide therapy, rehydration therapy should be performed. Treatment of children under 3 years of age should be carried out under the supervision of a doctor. In case of bacterial diarrhea with signs of systemic damage (deterioration of the general condition, fever, symptoms of intoxication or infection), you should consult a doctor to decide whether to prescribe antimicrobial drugs of systemic action. If you experience symptoms of hypersensitivity (shortness of breath, skin rash, pruritus), you should stop taking the drug. Alcohol consumption during nifuroxazide therapy is prohibited. Due to the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed). Nifural® suspension contains 1000 mg of sucrose in 5 ml. Accordingly, the sucrose content in a single dose of 2.5 ml of suspension is 0.04165 “bread units” (XE), and in a single dose of 5 ml – 0.0833 XE. The daily dose of sucrose is 0.0833 XE when taking 2.5 ml of suspension 2 times a day and 0.125 XE when taking 2.5 ml of suspension 3 times a day. The daily dose of sucrose is 0.250 XE when taking 5 ml of suspension 3 times a day and 0.333 XE when taking 5 ml of suspension 4 times a day. The 96% ethanol content of Nifural®suspension is 1%. The minimum single dose of the drug corresponding to 100 mg of nifuroxazide (2.5 ml suspension) contains 0.02 g of ethanol (in terms of absolute alcohol), and the maximum daily dose corresponding to 800 mg of nifuroxazide (5 ml suspension 4 times a day) contains 0.16 g of ethanol (in terms of absolute alcohol). Influence on the ability to drive vehicles and mechanicsthe drug does not affect the ability to drive vehicles and mechanisms.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf

life is 3 years.

Active ingredient

Nifuroxazide

Dosage form

Oral suspension